Carasent マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Daniel Ohman

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2yrs
CEOの所有権	0.2%
経営陣の平均在職期間	2yrs
取締役会の平均在任期間	2.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Daniel Ohman (44 yo)

2yrs

在職期間

Mr. Daniel Ohman was the Chief Executive Officer and President of GHP Specialty Care AB (publ) (formerly Global Health Partner AB (publ) since November 4, 2013 and served as its Business Area Manager of VG...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Svein Bjornstad	Chief Financial Officer	3.3yrs	データなし	0.49% € 577.3k
Daniel Ohman	Chief Executive Officer	2yrs	データなし	0.22% € 263.0k
Johan Eltes	Chief Technical Officer	2.1yrs	データなし	データなし
Jon Schultz	Legal Counsel	no data	NOK 45.00k	データなし
Stefan Jernberg	Chief Compliance Officer	less than a year	データなし	データなし
Chris Damvakaris	Vice President of Sales & Business Development	no data	NOK 723.00k	データなし
Cornelia Broqvist	Chief Marketing Officer	2.2yrs	データなし	データなし
Anna Larsson	People and Culture Manager	no data	データなし	データなし
Vilma Jonson	Head of Strategy	1.2yrs	データなし	0.033% € 39.4k

2.0yrs

平均在職期間

経験豊富な経営陣: C34の経営陣は経験豊富であると考えられます ( 2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Tomas Meerits	Director	1.5yrs	データなし	データなし
Camilla Skoog	Independent Director	2.6yrs	データなし	0.013% € 15.3k
Ulrika Sundling	Independent Director	2.6yrs	データなし	0.028% € 32.6k
Petri Niemi	Independent Chairman of the Board	2.1yrs	データなし	0.017% € 20.0k
Henric Carlsson	Independent Director	less than a year	データなし	データなし

2.1yrs

平均在職期間

54yo

平均年齢

経験豊富なボード: C34の取締役会は経験豊富ではない ( 2.1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Carasent マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

High number of new and inexperienced directors

Carasent ASA Announces Changes to Its Board

Chief Executive Officer recently bought €121k worth of stock

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings released: kr0.03 loss per share (vs kr0.06 loss in 3Q 2023)

New minor risk - Share price stability

High number of new and inexperienced directors

Eg Norge A/S cancelled the acquisition of Carasent ASA (OB:CARA).

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings released: kr0.60 loss per share (vs kr0.39 profit in FY 2022)

Chief Executive Officer recently bought €121k worth of stock

Full year 2023 earnings released: kr0.64 loss per share (vs kr0.39 profit in FY 2022)

Founder recently bought €2.4m worth of stock

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Carasent Asa Approves Dividend

Second quarter 2023 earnings released: kr0.64 loss per share (vs kr0.03 profit in 2Q 2022)

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Full year 2022 earnings released

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: kr0.13 (vs kr0.28 loss in 3Q 2021)

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Second quarter 2022 earnings released: EPS: kr0.03 (vs kr0.34 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: kr0.32 (vs kr0.14 loss in 1Q 2021)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings released: kr0.002 loss per share (vs kr0.85 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

Revenue misses expectations

New 90-day high: €3.76

Carasent ASA, Annual General Meeting, Jun 03, 2021

New 90-day high: €3.42

Carasent ASA Appoints Dennis Höjer as CEO

Carasent ASA (OB:CARA) acquired Avans Soma AS from Rieber & Søn ASA and others for approximately NOK 120 million.

New 90-day high: €2.59

Third quarter earnings released

Third quarter earnings released

Chairman recently sold €2.1m worth of stock

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14